Andrea Zimmer, MD
Infectious Disease · Omaha, NENPI 1295997336
Payments from drug & device makers
What this record shows
That places this record below the midpoint for infectious disease clinicians in NE, where the typical reported total is $141.
No general payments reported
No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.
Across 4 payments — averaging $49,063 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$196K
How this compares
$0 in reported general payments places this provider in the 10th percentile of 55 infectious disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ampicillin Sodium | 16 | $1,243 |
| Sodium Chloride0.9 % Sodium Chloride | 23 | $115 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Omaha
- Rudolf KotulaOmaha$221K
- Marvin BittnerOmaha$100K
- Mark RuppOmaha$76K
- Trevor VanschooneveldOmaha$56K
- Nada FadulOmaha$26K
- Alison FreifeldOmaha$15K
- Amir GholamiOmaha$12K
- Andre KalilOmaha$11K
- Kelly CawcuttOmaha$11K
- Diana FlorescuOmaha$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.